Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Aprea Therapeutics Announces Acceptance of Abstracts
DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (Aprea, or the Company), a clinical stage biopharmaceutical company focused on precision oncology...
DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (œAprea, or the œCompany), a clinical stage biopharmaceutical company focused on precision oncology...
DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (œAprea, or the œCompany), a clinical-stage biopharmaceutical company focused on precision oncology...
DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (œAprea, or the œCompany), a clinical-stage biopharmaceutical company focused on precision oncology...
DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (œAprea, or the œCompany), a clinical stage biopharmaceutical company focused on precision oncology...